

BTK Antibody (N-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP13546a**Specification**

BTK Antibody (N-term) - Product Information

Application	IHC-P, WB,E
Primary Accession	Q06187
Other Accession	P35991 , Q8JH64 , NP_000052.1
Reactivity	Human
Predicted	Chicken, Mouse
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Calculated MW	76281
Antigen Region	27-55

BTK Antibody (N-term) - Additional Information**Gene ID** 695**Other Names**

Tyrosine-protein kinase BTK, Agammaglobulinemia tyrosine kinase, ATK, B-cell progenitor kinase, BPK, Bruton tyrosine kinase, BTK, AGMX1, ATK, BPK

Target/Specificity

This BTK antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 27-55 amino acids from the N-terminal region of human BTK.

Dilution

IHC-P~~1:10~50

WB~~1:1000

E~~Use at an assay dependent concentration.

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

BTK Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

BTK Antibody (N-term) - Protein Information

Name BTK**Synonyms** AGMX1, ATK, BPK

Function Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling (PubMed:[19290921](#)). Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation (PubMed:[19290921](#)). After BCR engagement and activation at the plasma membrane, phosphorylates PLCG2 at several sites, igniting the downstream signaling pathway through calcium mobilization, followed by activation of the protein kinase C (PKC) family members (PubMed:[11606584](#)). PLCG2 phosphorylation is performed in close cooperation with the adapter protein B-cell linker protein BLNK (PubMed:[11606584](#)). BTK acts as a platform to bring together a diverse array of signaling proteins and is implicated in cytokine receptor signaling pathways (PubMed:[16517732](#), PubMed:[17932028](#)). Plays an important role in the function of immune cells of innate as well as adaptive immunity, as a component of the Toll-like receptors (TLR) pathway (PubMed:[16517732](#)). The TLR pathway acts as a primary surveillance system for the detection of pathogens and are crucial to the activation of host defense (PubMed:[16517732](#)). Especially, is a critical molecule in regulating TLR9 activation in splenic B-cells (PubMed:[16517732](#), PubMed:[17932028](#)). Within the TLR pathway, induces tyrosine phosphorylation of TIRAP which leads to TIRAP degradation (PubMed:[16415872](#)). BTK also plays a critical role in transcription regulation (PubMed:[19290921](#)). Induces the activity of NF- kappa-B, which is involved in regulating the expression of hundreds of genes (PubMed:[19290921](#)). BTK is involved on the signaling pathway linking TLR8 and TLR9 to NF-kappa-B (PubMed:[19290921](#)). Acts as an activator of NLRP3 inflammasome assembly by mediating phosphorylation of NLRP3 (PubMed:[34554188](#)). Transiently phosphorylates transcription factor GTF2I on tyrosine residues in response to BCR (PubMed:[9012831](#)). GTF2I then translocates to the nucleus to bind regulatory enhancer elements to modulate gene expression (PubMed:[9012831](#)). ARID3A and NFAT are other transcriptional target of BTK (PubMed:[16738337](#)). BTK is required for the formation of functional ARID3A DNA-binding complexes (PubMed:[16738337](#)). There is however no evidence that BTK itself binds directly to DNA (PubMed:[16738337](#)). BTK has a dual role in the regulation of apoptosis (PubMed:[9751072](#)). Plays a role in STING1- mediated induction of type I interferon (IFN) response by phosphorylating DDX41 (PubMed:[25704810](#)).

Cellular Location

Cytoplasm. Cell membrane; Peripheral membrane protein. Nucleus Membrane raft {ECO:0000250|UniProtKB:P35991}. Note=In steady state, BTK is predominantly cytosolic. Following B-cell receptor (BCR) engagement by antigen, translocates to the plasma membrane through its PH domain Plasma membrane localization is a critical step in the activation of BTK. A fraction of BTK also shuttles between the nucleus and the cytoplasm, and nuclear export is mediated by the nuclear export receptor CRM1.

Tissue Location


Predominantly expressed in B-lymphocytes.

BTK Antibody (N-term) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


BTK Antibody (N-term) - Images



BTK Antibody (N-term) (Cat. #AP13546a) western blot analysis in HL-60 cell line lysates (35ug/lane). This demonstrates the BTK antibody detected the BTK protein (arrow).



Western blot analysis of BTK (arrow) using rabbit polyclonal BTK Antibody (N-term) (Cat. #AP13546a). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected (Lane 2) with the BTK gene.



BTK Antibody (N-term) (Cat. #AP13546a) immunohistochemistry analysis in formalin fixed and paraffin embedded human tonsil tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of BTK Antibody (N-term) for immunohistochemistry. Clinical relevance has not been evaluated.

BTK Antibody (N-term) - Background

The protein encoded by this gene plays a crucial role in B-cell development. Mutations in this gene cause X-linked agammaglobulinemia type 1, which is an immunodeficiency characterized by the failure to produce mature B lymphocytes, and associated with a failure of Ig heavy chain rearrangement.

BTK Antibody (N-term) - References

Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
Ng, Y.Y., et al. Leukemia 24(9):1617-1630(2010)
Segat, L., et al. Vaccine 28(10):2201-2206(2010)
Marcotte, D.J., et al. Protein Sci. 19(3):429-439(2010)
Liu, Z., et al. J. Immunol. 184(1):244-254(2010)